Thymosin Alpha-1

Thymosin Alpha-1 is a naturally occurring peptide first isolated from thymic tissue by Dr. Allan Goldstein in the 1970s and subsequently manufactured synthetically as Thymalfasin. The thymus — a lymphoid organ critical to T-cell development — produces Thymosin Alpha-1 as part of the thymosins, a family of peptides responsible for T-lymphocyte maturation and immune system calibration. Thymosin Alpha-1 is FDA approved in over 35 countries (marketed as Zadaxin by SciClone Pharmaceuticals) for treating chronic hepatitis B and C and as an immune adjuvant in cancer and HIV contexts. While not FDA approved in the United States, it has been studied in more than 70 clinical trials and has a clinical data base that exceeds virtually all other peptides used in the research community. Beyond its established antiviral applications, TA-1 has attracted significant interest for aging-related immune decline (immunosenescence), recovery from infection or surgery, and as an adjuvant to cancer immunotherapy.

T-cell function enhancement is the mechanistic core of TA-1's activity. It stimulates thymocyte differentiation, promotes T-helper cell activation, and enhances cytotoxic T-lymphocyte response — the cellular arm of adaptive immunity responsible for viral clearance and tumor surveillance. This makes it particularly valuable in conditions of T-cell exhaustion or immunosenescence. Antiviral efficacy is the best-documented clinical benefit. Phase III trials have demonstrated meaningful improvements in hepatitis B surface antigen clearance and sustained virologic response in hepatitis C when TA-1 is used as part of combination antiviral therapy. Natural killer (NK) cell enhancement contributes to both antiviral and anti-tumor activity. NK cells are innate immune effectors that do not require prior antigen sensitization — their activation by TA-1 provides rapid immune response to novel threats. COVID-19 research during the pandemic produced multiple published studies from China showing improved outcomes in severe COVID-19 patients treated with Thymosin Alpha-1, consistent with its T-cell and NK cell regulatory mechanism.

Thymosin Alpha-1 is one of the best-tolerated peptides used in clinical medicine. In over 70 clinical trials covering thousands of patients, significant adverse effects have been rare. Injection site reactions — mild redness, swelling, or soreness — are the most frequently reported adverse events, and these are generally mild and transient. Hypersensitivity reactions are possible as with any injectable biological compound, though they have been rare in clinical trial populations. Because TA-1 modulates rather than broadly stimulates the immune system, the cytokine storm risk associated with non-selective immune activators is largely absent. It is considered to have an immunomodulatory rather than immunostimulatory profile — calibrating immune response rather than simply amplifying it.

Clinical standard dose: 1.6 mg (approximately 1.5 mg by convention) SubQ twice per week. This is the dose established in clinical trials for hepatitis and other approved indications. Preventive/maintenance use: Some longevity and immune optimization practitioners use 1–1.5 mg once per week as a maintenance dose outside of active infection or illness. Acute use (illness, surgery): Higher frequency dosing (1.5 mg three times per week) is used by some practitioners during active infection or perioperative immune support. Cycle length: TA-1 is often used in cycles of 4–6 weeks for acute immune support, or as an ongoing once-weekly maintenance for general immune optimization in older adults. Storage: Requires refrigeration and protection from light, standard for most peptides.

United States: Not FDA approved but not a controlled substance. Legal as a research chemical. Some US compounding pharmacies prepare it with physician oversight. International: Approved as Zadaxin in over 35 countries including China, Russia, Italy, and Singapore for specific indications. In approved markets, legitimate pharmaceutical-grade product is available through standard medical channels. WADA: Not on the WADA prohibited list. Athletes can confirm current status, but TA-1 is not considered a performance-enhancing substance in the traditional athletic sense.

TA-1 + BPC-157: Complementary immune and repair support. BPC-157 addresses tissue healing; TA-1 provides immune modulation support during recovery from injury or illness. TA-1 + Epithalon: A longevity-focused immune aging protocol. Epithalon targets telomere biology; TA-1 addresses immunosenescence — the age-related decline in T-cell function. This combination reflects the aging immune system from two distinct angles. TA-1 as an adjuvant: In clinical settings, TA-1 is used alongside standard antiviral or chemotherapy protocols to enhance immune response. In the research community, similar adjuvant-style use alongside other immune-relevant compounds is common.

Thymosin Alpha-1 — Common Questions